Please login to the form below

Not currently logged in
Email:
Password:

Athenex expands global leadership team

Dr Simon Pedder and Raymond Yeung join the pharmaceutical firm

Global specialty oncology pharmaceutical company Athenex has appointed Dr Simon Pedder and Raymond Yeung to its global leadership team.

Based in the US, Dr Pedder joins as vice president of corporate strategy and business development.

He brings over 25 years of executive management experience in drug development, including as vice president of oncology pharma business at Hoffman-LaRoche, vice president and head of drug development at Shearwater Corporation and most recently as president and chief executive officer for Cellectar Biosciences.

Dr Pedder said: “Athenex has a very strong executive management team … [and] coupled with their unique business model and deep oncology portfolio, Athenex is going to be a leader in the US and China, reshaping traditional treatment options for cancer patients.

“I am looking forward to joining their leadership team to further their business and scientific strategies.”

Meanwhile, Raymond Yeung joins Athenex's Hong Kong office as its new senior director and deputy head of clinical research and regulatory affairs, Asia-Pacific.

Prior to joining the oncology specialist firm, Yeung held several senior management positions in preclinical and clinical development, including managing director of Albany Molecular Research Inc, general manager at Fortune Pharmacal and director of Asia-Pacific at MSD Pharma Services.

Yeung said: “I am delighted to come out of retirement to work with [Athenex's] leadership team to contribute towards the development of new medicine to help patients and also to bridge the biotechnology/pharmaceutical space between the US and China.”

15th February 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics